Biochemical Markers of Bone Turnover

BIOCHEMICAL MARKERS OF BONE TURNOVER

With the ageing population in most countries, disorders of bone and mineral metabolism are becoming increasingly relevant to everyday clinical practice. Consequently, the interest in, and the need for effective measures to be used in screening, diagnosis and follow up of such pathologies have markedly grown. Together with clinical and imaging techniques, biochemical tests play an important role in the assessment and differential diagnosis of metabolic bone diseases. These biochemical markers are non-invasive, comparatively inexpensive when applied correctly, helpful tools in the diagnostic and therapeutic assessment of metabolic bone diseases.

Bone is constantly undergoing a metabolic process called remodeling. This includes a degradation process, bone resorption, mediated by the action of osteoclasts, and a building process, bone formation, mediated by the action of osteoclasts. Remodeling is required for the maintenance and overall health of bone and is tightly coupled; that is, resorption and formation is in balance. In abnormal state of bone metabolism, this process becomes uncoupled and when resorption, exceeds formation, this result in a net loss of bone.

Osteoporosis is a metabolic bone disease characteristics by abnormal bone remodeling. It is systematic skeletal disease characterized by low bone mass and microarchitechtural deterioration of bone tissue with a consequent increase in susceptibility of fractures. The most common type of osteoporosis occurs in post-menopausal women as a result of estrogen deficiency produced by the cession of ovarian function. Restoration of premenopausal estrogen levels by replacement therapy prevents bone loss and osteoporosis. Osteoporosis can also results from an inadequate peak boke mass during the growing years, an aged related imbalance of bone remodeling with not excess of resorption and a number of clinical conditions and therapies that induce bone loss or bone remodeling imbalances. These include endocrine diseases such as hypogonadism, hyperthyroidism, and hypercorticolism; gastrointestinal diseases related to nutrition and mineral metabolism; connective tissue disease; multiple myeloma; chronic immobilization, alcoholism, and chronic therapy with heparin or corticosteroidsd. Other diseases characterized by bone remodeling include Paget’s disease and metastasis to bone.

Bone turnover markers, are indicators of bone metabolism derived from bone matric or bone cells. They are important diagnostic aid in the evaluation and management of osteoporosis. Bone markers allow for efficient therapy monitoring and compliance testing of osteoporotic patients. They can also help in fracture risk prediction. The international osteoporosis foundation (IOF) supports the use of bone markers with published guidelines.

therapeutic

therapeutic1

Markers of Bone Formation:

Bone formation markers are products of osteoblast expressed during different phase of osteoblast development. They are considered to reflect different aspects of osteoblast function and of bone formation. All markers of bone formation are measured in serum or plasma.

  1. Bone alkaline phosphatase

The activity of bone ALP is elevated with increased osteoblast activity such as in Paget’s disease, high turnover osteoporosis, hyperparathyroidism, osteomalacia and rickets etc. Advantages of using the marker

  • Long halflife if 1 to 2 days in serum
  • Unaffected by diurnal variation
  • Not affected by declining GFR, thus more useful than osteocalcin in impaired renal function
  • Highly sensitive & specific marker for diagnosis of Paget’s disease.

Bone APL is not a reliable marker in liver disease and in patients with abnormal level of 1,25 dihydroxy vitamin D.

  1. Osteocalcin

Osteocalcin is synthesized in the skeleton by osteoblasts the cells responsible for bone formation. Its synthesis is stimulated by 1,25 dihydroxyvitamin D and it is rapidly cleared by kidney, thus has a short half life. It is highly sensitive and specific maker of bone formation. Its levels are increased in hyperparathyroidism, Paget’s disease, high turnover osteoporosis hyperthyroidism, renal osteodystrophy, fracture, and acromegaly and are decreased in hyperparathyroidism. Growth hormone deficiency, during estrogen replacement therapy, during treatment of glucocorticoid, bisphosphonates, and calcitonin. Osteocalcin may be misleading in certain situations as it may be elevated in patients of renal failure and in patients on treatment of Vitamin D.

  1. Procollagen Peptides

Another test for assessing bone formation or osteoblastic collagen synthesis is determination of propeptides of type I collagen. Type I collagen is the most abundant collagen found in bone. It is also found in other tissues such as skin, dentin, cornea, vessels etc. and tendons in bone; collagen is synthesized as pre-procollagen containing both N and C terminal extensions. These extensions or propeptides are cleared from Type I collagen during fiber formation and circulate in blood. Assays are available both for the amino (N-) propeptide (P1NP) and the carboxy (C-) terminal propeptide (P1CP). But clinical relevance of P1CP is still in evaluation and serum P1CP appears to be of greater diagnostic validity. From practical point of view thermostability of P1NP is an advantage in that extended transport and storage times are well tolerated without significant loss of activity. Measurement of P1NP is helpful for assessing bone formation in patients treated with vitamin D or in patients with abnormal level of these hormones where osteocalcin and bone alkaline phosphatase may be misleading.

Markers of Bone Resorption

Marker of bone resorption include collagen cross links such as pyridinolines and N and C telopeptides, acid phosphatase, urinary galactosyl hydroxylysine and urinary hydroxyproline.

  1. Puridnolines (Deoxypyridinoline (DPD) and pyridinoline (PYD)

PYD and DPD are formed during the extracellular maturation of fibrillary collagens. They bridge several collagen peptides and mechanically stabilize the collagen molecule. During bone resorption, crosslinked collagens are proteolytically broken down and these cross linked components are released into circulation and urine. DPD is sound in significant amount in bone, ligaments and arota. DPD appears to be specific and sensitive markers of bone resorption for several reasons:

  • It is formed during collagen maturation and nor during biosynthesis. Thus originates only as degeneration product of mature matrix.
  • It does not appear to be metabolized prior to excretion in urine
  • Bone is the major source of DPD
  • DPD does not appear to be absorbed from the diet.

Thus, pyridinium cross links are currently viewed as the best indices for assessing bone resorption.

  1. Cross Linked telopeptides of Type I collagen

The cross linked telopeptides of type I collagen are derived from specific region of the collagen type I molecule, namely aminoterminal telopeptide (NTP) and Carboxy terminal (CTP) telopeptide.

Elevated levels of pyridinolined and telopeptides have been reported in osteoporosis, Paget’s Disease, metastic bone disease, primary and secondary hyperthyroidism, and other disease with increased bone resorption. When postmenopausal women are compared with premenopausal controls, telopeptides are usually are increased more than other markers of resorption and formation. Response of antiresorptive therapy is generally greatest with teleopeptides, intermediate with total pyridnolines and lowest with free pyridinolines.

CLINICAL UTILITY OF BONE MARKERS

Therapy Monitoring

The most persuasive evidence to date for the use of bone markers is in the area of monitoring of osteoporosis treatment. The aim of the treatment is to prevent fractures. Biphosphonates, estrogens and ralozifene decrease bone resorption and bone formation markers.; strontium ravealte treatment causes a mild reduction in bone resorption markers and a slight increase in bone formation markers; teriparatide (recombinant PTH) increases both bone formation and bone resorption markers. The advantage of suing bone markers instead of BMD is the significant changes in the bone markers can be observed after three to six months after initiation of therapy, whereas changes in BMD becomes significant only after 18 to 24 months; a long time to detect treatment failure. The reduction in fracture risk following antiresorptive treatment was seen early similar to change in bone markers, whereas the change in BMD are gradual and later. No surprisingly change in bone markers explains a much greater proportion od reidction in fracture risk than any change in BMD. Taken together, these data suggest bone markers are arguably better tools than BDM for monitoring antiresorptive treatment.

Fractures risk assessment

The diagnosis of osteoporosis is based on bone density scanning by virtue of WHO definition of osteoporosis and patients with a low bone density have increased risk of fracture. However a considerable body of data indicates that bone markers predict bone markers predict bone loss independent of bone density; individuals with increased bone turnover loose bone at a faster rate than subjects with normal or low bone turnover markers. Bone turnover markers, in combination with other risks factors of osteoporosis fractures, may be used to describe fracture risk or intervention thresholds. The relative fracture risk, as defined by either low BMD or an increased bone turnover marker, I similar and increased fracture is accentuated when both are present. Thus, in clinical practice, increased bone turnover markers in the presence of a low BMD would favor initiation of treatment for that patient.

To identify noncompliant patient

Bone markers react very sensitively and quickly (within days) to irregular drug taking and therefore rapidly reveal inconsistent intake of medications. Positive feedback to the patient has been shown to improve the patient’s adherence to the prescribed medication. Studies have shown that up to 50% of patients stop treatment too early and medication is taken irregularly. Adherent patients were shown to suffer fewer fractures and to incur lower hospital costs.

To identify non responders to therapy

Most therapies are highly efficient as proven in many studies and true treatment failures are rare. However there are some patients who do not respond to therapy for the following reasons:

Bone markers are able to identify these patents at a very early point in time to allow for appropriate measures to prevent future fractures.

bone

 

Google Reviews

kamesh vijaykumar
kamesh vijaykumar
2024-05-31
Good service with affordable cost.Thanks
prashanthi duvvuri
prashanthi duvvuri
2023-12-13
Quick service and excellent detailed reports provided.
Saikrishnan Ns
Saikrishnan Ns
2023-02-06
Very interactive, responding well, and well executed. I would like to recommend to all my friends and relatives. Good job. Excellent. Continue to help

Leave A Comment

Your email address will not be published *

About Author

about

Thyrocare Technologies Limited is India’s first and most advanced Totally Automated Laboratory having its strong presence in more than 2000 cities / towns in India and internationally.

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • Rating
  • Price
  • Availability
  • Add to cart
  • Description
  • Additional information
  • shortcode
  • Image
  • Image
Click outside to hide the comparison bar
Compare